Related Experiment Videos
Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits
1Department of Neurology, University Hospital Rotterdam, The Netherlands.
Insights
Patients with nonrheumatic atrial fibrillation (NRAF) and recent TIA or stroke face high recurrence risk. Oral anticoagulants significantly reduce this risk, offering a two-thirds benefit similar to primary prevention.
Area of Science:
- Neurology
- Cardiology
- Clinical Medicine
Background:
- Nonrheumatic atrial fibrillation (NRAF) patients with recent TIA or stroke have a high annual stroke recurrence risk (~12%).
- Oral anticoagulant therapy (OAC) demonstrates significant efficacy in reducing stroke risk in this population.
Purpose of the Study:
- To review the efficacy and safety of anticoagulant therapy for stroke prevention in NRAF patients.
- To discuss alternative antiplatelet therapies and the role of heparin in acute stroke management.
Main Methods:
- Analysis of two randomized clinical trials on oral anticoagulant therapy.
- Review of current guidelines and evidence regarding anticoagulation intensity and alternative treatments.
Main Results:
- Oral anticoagulant therapy reduces stroke risk by approximately two-thirds in NRAF patients with recent TIA or stroke.
- Optimal therapeutic intensity for oral anticoagulants is an International Normalized Ratio (INR) of 2.0-3.0.
- Aspirin and ibuprofen are less effective alternatives when anticoagulation is contraindicated.
- Subcutaneous heparin is not recommended in the first two weeks post-major stroke due to increased bleeding risk.
Conclusions:
- Oral anticoagulation is highly effective for secondary stroke prevention in NRAF patients.
- Risk stratification for stroke recurrence is possible using clinical information.
- Careful consideration of treatment timing and agent choice is crucial for optimizing outcomes and minimizing risks.
Abstract:
Patients with nonrheumatic atrial fibrillation (NRAF) and a recent transient ischemic attack (TIA) or nondisabling ischemic stroke have a high risk of stroke recurrence of about 12% per year. Two randomized clinical trials have shown that oral anticoagulant therapy reduces the risk by two thirds, very similar to the benefit in primary prevention. The optimal intensity is INR 2.0-3.0. In case of a containdication to AC, aspirin and ibuprofen are safe, but less effective, alternatives. During the first 2 weeks following AF-related major stroke, the benefit of subcutaneous heparin is offset by a higher risk of secondary cerebral bleeding, and therefore cannot be recommended, at present, during that period. The risk of stroke recurrence can be predicted by means of easily available clinical information.